Swipe for more

• February 11, 2025

  bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

  bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid has obtained clearance from the U.S. Food and Drug Administration (FDA). This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis — all from one sample, with results available in approximately one hour.

  Read more
  

• January 13, 2025

  bioMérieux strengthens its point of care presence with the acquisition of the immunoassay start-up SpinChip

  bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”), a privately held Norwegian diagnostics company that has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted to near patient testing as it can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments.

  Read more
  

• January 13, 2025

  bioMérieux to present at the 43rd Annual J.P. Morgan HealthCare Conference

  Marcy l’Étoile, France, January 13, 2025 – bioMérieux, a world leader in the field in vitro diagnostics, today announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, USA, from January 13 to 16, 2025.

  Read more